Lilly(Eli) & Company
NYSE: LLY
$797.58
+$21.20 (+2.7%)
Closing Price on November 7, 2024
LLY Articles
Investors never take kindly to a 2.45% sell-off, like the one seen in the S&P 500, and they may be looking to shift into dividend-paying large caps, which will remain in demand as rates continue...
Published:
Last Updated:
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
Published:
Last Updated:
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
Published:
Last Updated:
As one of the largest pharmaceutical companies on the street, Eli Lilly helps to set the tempo for the industry. Currently the company is in the middle of a very dynamic product launch.
Published:
Last Updated:
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
Published:
Last Updated:
With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great total return vehicle for the rest of this year and into 2017.
Published:
Last Updated:
Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year.
Published:
Last Updated:
Eli Lilly and Co. (NYSE: LLY) is watching its shares make a decent gain on Wednesday following a U.S. Food and Drug Administration (FDA) vote. The FDA Advisory Committee voted 12-11 that substantial...
Published:
Last Updated:
With the market pushing through to all-time highs, we are looking for solid total return ideas for investors. Total return is one of the best ways to help improve the chances for overall investing...
Published:
Last Updated:
The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations at the conference.
Published:
Last Updated:
Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology (ASCO) annual meeting, and it has issued a report on what it is looking for.
Published:
Last Updated:
The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.
Published:
Last Updated:
Volumes tend to dry up in the summer as traders and investors go on vacation, making it all that much easier for the short-sellers to exploit headline and market risk.
Published:
Last Updated:
Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue to stay around.
Published:
Last Updated:
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these...
Published:
Last Updated: